@article{e9a62f2bb3db4fa79cb5600d1d4fb906,
title = "Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal",
abstract = "Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term {\textquoteleft}active{\textquoteright} secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms “progressive multiple sclerosis”, “primary progressive multiple sclerosis”, “secondary progressive MS”. Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.",
keywords = "Multiple sclerosis, progression, progressive, progressive multiple sclerosis",
author = "Thompson, {Alan J.} and William Carroll and Olga Ciccarelli and Giancarlo Comi and Anne Cross and Alexis Donnelly and Anthony Feinstein and Fox, {Robert J.} and Anne Helme and Reinhard Hohlfeld and Robert Hyde and Pamela Kanellis and Douglas Landsman and Catherine Lubetzki and Marrie, {Ruth Ann} and Julia Morahan and Xavier Montalban and Bruno Musch and Sarah Rawlings and Marco Salvetti and Finn Sellebjerg and Caroline Sincock and Smith, {Kathryn E.} and Jon Strum and Paola Zaratin and Timothy Coetzee",
note = "Funding Information: A. Cross has done paid consulting for Biogen, Bristol Myers Squibb (Celgene), EMD Serono, Genentech/Roche, Greenwich Biosciences, Horizon Therapeutics, Janssen, Novartis, and TG Therapeutics and has contracted research funded by EMD Serono and Genentech. Funding Information: RAM receives research funding from CIHR, the MS Society of Canada, Research Manitoba, the CMSC, National MS Society, US Department of Defense, and Crohn{\textquoteright}s and Colitis Canada. She is supported by the Waugh Family Chair in Multiple Sclerosis. She is a co-investigator on studies funded by Biogen Idec and Roche. Funding Information: WM Carroll reports honoraria and travel assistance for participation in industry sponsored meetings from and has provided advice to Biogen, Novartis, Genzyme, Sanofi, Aventis, Merck, and Celgene and has received travel support from the International Progressive MS Alliance, PACTRIMS and the World Federation of Neurology. Publisher Copyright: {\textcopyright} The Author(s), 2021.",
year = "2022",
month = jan,
doi = "10.1177/13524585211059766",
language = "English",
volume = "28",
pages = "16--28",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",
}